Despite the limitations of a retrospective study, and its small sample size, it adds relevant information regarding histological analyses according to the Oxford classification of IgAN. 8, 9 A high ...

In the ever-dynamic and fast-moving world of semiconductors, why do some old transistors like 2N3904 keep on going for decades? Bill Schweber takes a closer look at this remarkable premise while ...

Researchers in China say they have created a new silicon-free transistor that could significantly boost performance while reducing energy consumption. The team says this development represents a ...

The 2D transistor’s design looks like a series of interwoven bridges. Photo: Peking University/modified by ZME Science. At Peking University, a group of Chinese scientists may have just turned ...

“This is a meaningful addition to our renal portfolio as we continue driving innovation in kidney care, following our recent approvals of treatments for IgAN and C3G,” Shreeram Aradhye, Novartis’ ...

SAN DIEGO & ST. GALLEN - The European Commission has granted standard marketing authorization to FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN), a rare kidney disease, ...

One such partner, Synopsys, announced early Tuesday it has just certified AI-driven digital and analog design flows for the Intel 18A process node in addition to production-ready EDA flrow for Intel ...

We remain dedicated to working with our partners, regulators, and healthcare providers to expand access and improve outcomes for those affected by IgAN.” “The decision by the European ...

We remain dedicated to working with our partners, regulators, and healthcare providers to expand access and improve outcomes for those affected by IgAN.” “The decision by the European Commission is an ...

SAN FRANCISCO and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”), a biotechnology company focused on developing best-in ...

Organic TFTs are shaking up the display world, offering flexible new design possibilities that challenge the long-standing dominance of amorphous-silicon transistors. OTFTs vs. a-Si transistors ...

The paradigm shift toward mechanism-based therapies promises to revolutionize IgAN management, potentially modifying disease course rather than merely managing symptoms and complications.